UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Exploratory subgroup identification in the heterogeneous Cox model: A relatively simple procedure

Statistics in medicine, 2024-09, Vol.43 (20), p.3921-3942

2024

Volltextzugriff (PDF)

CAPITAL: Optimal subgroup identification via constrained policy tree search

Statistics in medicine, 2022-09, Vol.41 (21), p.4227-4244

2022

Volltextzugriff (PDF)

Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics

Clinical pharmacology and therapeutics, 2022-03, Vol.111 (3), p.664-675

2022

Volltextzugriff (PDF)

Identifying individual risk rare variants using protein structure guided local tests (POINT)

PLoS computational biology, 2019-02, Vol.15 (2), p.e1006722-e1006722

2019

Volltextzugriff (PDF)

Association test using Copy Number Profile Curves (CONCUR) enhances power in rare copy number variant analysis

PLoS computational biology, 2020-05, Vol.16 (5), p.e1007797

2020

Volltextzugriff (PDF)

Survival analysis using a 5‐step stratified testing and amalgamation routine (5‐STAR) in randomized clinical trials

Statistics in medicine, 2021-08, Vol.40 (19), p.4341-4343

2021

Volltextzugriff (PDF)

Survival analysis using a 5‐step stratified testing and amalgamation routine (5‐STAR) in randomized clinical trials

Statistics in medicine, 2020-12, Vol.39 (30), p.4724-4744

2020

Volltextzugriff (PDF)

Voriconazole pharmacogenetics – Authors' reply

The Lancet (British edition), 2021-08, Vol.398 (10300), p.578-579

2021

Volltextzugriff (PDF)

P1065: UPDATED RESULTS FROM AN OPEN‐LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD‐1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e0274602-n/a

2023

Volltextzugriff (PDF)

P1068: UPDATED RESULTS FROM AN OPEN‐LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD‐1 TREATMENT

HemaSphere, 2023-08, Vol.7 (S3), p.e5990067-n/a

2023

Volltextzugriff (PDF)

Analysis of composite time-to-event endpoints in cardiovascular outcome trials

Clinical trials (London, England), 2024-08, p.17407745241267999

2024

Volltextzugriff (PDF)

Is inadequate risk stratification diluting hazard ratio estimates in randomized clinical trials?

Clinical trials (London, England), 2024-02, p.17407745231222448-17407745231222448

2024

Volltextzugriff (PDF)

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.1693-1693

2023

Volltextzugriff (PDF)

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.1725-1725

2023

Volltextzugriff (PDF)

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.4440-4440

2023

Volltextzugriff (PDF)

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

Blood, 2022-11, Vol.140 (Supplement 1), p.768-770

2022

Volltextzugriff (PDF)

Association test using Copy Number Profile Curves

PLoS computational biology, 2020-05, Vol.16 (5)

2020

Volltextzugriff (PDF)

Flexible KernelMachineMethods for Complex Genomic Data

Marceau West, Rachel Elizabeth

2017

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(17)
Dissertationen
(1)

Sprache

Englisch
(18)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Exploratory subgroup identification in the heterogeneous Cox model: A relatively simple procedure

CAPITAL: Optimal subgroup identification via constrained policy tree search

Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics

Identifying individual risk rare variants using protein structure guided local tests (POINT)

Association test using Copy Number Profile Curves (CONCUR) enhances power in rare copy number variant analysis

Survival analysis using a 5‐step stratified testing and amalgamation routine (5‐STAR) in randomized clinical trials

Survival analysis using a 5‐step stratified testing and amalgamation routine (5‐STAR) in randomized clinical trials

Voriconazole pharmacogenetics – Authors' reply

P1065: UPDATED RESULTS FROM AN OPEN‐LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD‐1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

P1068: UPDATED RESULTS FROM AN OPEN‐LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD‐1 TREATMENT

Analysis of composite time-to-event endpoints in cardiovascular outcome trials

Is inadequate risk stratification diluting hazard ratio estimates in randomized clinical trials?

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

Association test using Copy Number Profile Curves

Flexible KernelMachineMethods for Complex Genomic Data

Suchergebnisse filtern